FTFinancial Times·1hBusiness
score-0.60
Novo Nordisk Refocuses Diversification Strategy After Cardiovascular Trial Setback, Shares Fall 10%
Original
Novo Nordisk shares drop 10% after cardiovascular drug trial disappoints
“Headline uses negative verbs 'drop' and 'disappoints' to emphasize financial loss and failed expectations.”